NewsRelease
BiotechSupport Group introduces new product information and presents posterat the ASMS 2022 Conference on Mass Spectrometry & Allied Topics
MONMOUTHJUNCTION, NJ,June22, 2022 -- Biotech Support Group presented new uses for its productsin LC-MS analysis, and presented a poster with research collaboratorsat the ASMS 2022 Conference, in Minneapolis MN, June 5-9, 2022.The information provided includes:
Albumin & IgG Removal Products
Thisproduct information sheet describes the BSG advantages for Albumin &IgG Removal and lists select references whereby these products wereused for LC-MS analysis.
Click image to download
Hemoglobin Removal Products
This product information sheet describes the BSG advantages in Hemoglobin removal and lists select references whereby these products were used for LC-MS analysis.
Click image to download
Lipid Removal & Clarification
This product information sheet describes the BSG advantages for lipid removal and clarification and lists select references whereby these products were used for LC-MS analysis.
Click image to download
Proteomic Sample Prep & Enrichment
This product information sheet describes the common features for all of our products and their collective advantages in proteomic analysis. A select list of references is included describing how these advantages were used in referenced journal research.
Click image to download
NuGel™ bead formats support high throughput sample prep and automation
This product information sheet describes the NuGel™ features:
• 50 µm porous silica bead that is passivated through a proprietary coating exceedingly fast filtration and settling characteristics,
• perfectly suited to high throughput and automation
• customizable formats
• not derived from immuno-affinity
• selective depletion of Albumin, Albumin & lgG, and Hemoglobin.
Data using the DPX Technologies, high-throughput XTR tip format is provided.
Click image to download
Poster
Stromalconditioning correlations using Stroma Liquid Biopsy™ blood-basedbiomarkers and tumor tissue profiles
MattKuruc1;Cor J. Ravensbergen2;Wilma E. Mesker2;Rob Tollenaar2;Yurivan der Burgt2;SwapanRoy 1
1BiotechSupport Group LLC, Monmouth Junction, NJ; 2LeidenUniversity Medical Center, Leiden, Netherlands
Clickimage to download
Briefdescription: The concept of liquid biopsy has generated muchscientific and commercial enthusiasm as it starts with a veryaccessible sample type - a body fluid, typically blood, rather thanconventional solid tissue biopsy. Nevertheless, most currentliquid biopsy efforts focus on genomic data which relies on a largelyreductionist view that tumors form and progress only through thecollection of its immortalized cells. While the current TNM stagingsystem stratifies patients based on the extent of cancer spread, itis now overwhelmingly apparent that throughout cancer progression,tumor promoting inflammation is intrinsic to progressive disease. Soalthough the TMN system provides guidance for clinical management,outcomes from local tumor excision at one end of the spectrum andadjuvant therapy at the other end, vary greatly among the variety ofpossible treatments within these stages. There remains great need formore personalized biomarkers to differentiate patient sub-populationsand treatment options. For this, the supporting tumormicroenvironments or stroma, must also be evaluated. Using proteomicsand gene expression, we highlight the importance of the systemicinflammatory response to the presence of cancer anywhere in the body,largely derived from an unresolved innate immune response. Also, thatthe tumor-stroma microenvironment is an important prognosticparameter for patients with epithelial cancer types. We conclude thatthe stromal conditioning protein blueprint, as captured by the StromaLiquid Biopsy™ panel, encompasses a more discreet stratification ofthe tumor and patient prognosis, and offers new insights intotherapeutic strategies that might beneficially modulate thetumor-microenvironment.
“Thiswas a very successful meeting for us as we were able to first andforemost show how all our sample prep and enrichment products areadvantageously used in LC-MS analysis. Along with that, we were ableto share very exciting developments from our research collaborationwith Leiden University Medical Center,on our Stroma Liquid Biopsy™ platform. This panel ofcancer-associated proteins necessitates the use of LC-MS to determinenot only abundance levels but also functional attributes, whichcannotbe monitored by antigen presentation, aptamer or other like proteomicplatforms.”,states Dr. Swapan Roy, Ph.D., President and Founder of BiotechSupport Group.
Formore information on BSG & Leiden University Medical CenterCollaborative Research Agreement, see our joint press release:
https://www.biotechsupportgroup.com/Articles.asp?ID=570
Formore information on the BSG complete line of Albumin& IgG Removal products,visit:
https://www.biotechsupportgroup.com/Albumin-Removal-s/307.htm
Formore information on the BSG complete line of HemoglobinRemovalproducts, visit:
https://www.biotechsupportgroup.com/Hemoglobin-Removal-s/312.htm
Formore information visit:Cleanascite™Lipid Removal Reagent and Clarification,at
https://www.biotechsupportgroup.com/Lipid-Removal-s/316.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, and HemogloBind™ and HemoVoid™ for hemoglobinremoval. From these innovations, the company has acquiredknowledgebase and biomarker intellectual property assets that supportdiscoveries of protein markers from blood, with special emphasis onearly detection and personalized medical decisions for cancerpatients. For more information, gotohttps://www.biotechsupportgroup.com
ForBusiness Development, contact:MatthewKuruc 732-274-2866[email protected]